厄贝沙坦与氨氯地平治疗2型糖尿病合并高血压的临床研究

目的探讨厄贝沙坦联合氨氯地平治疗2型糖尿病合并高血压的临床效果。方法选取2011年1月至2012年10月期间首都医科大学宣武医院收治的132例2型糖尿病合并高血压患者,根据随机数字表法分为联合用药治疗组和美托洛尔单用组,每组66例,联合治疗组采用厄贝沙坦联合氨氯地平治疗,每次50 mg,每日3次,氨氯地平每次2.5 mg,每日1次,疗程90 d。美托洛尔单用组仅采用美托洛尔治疗,每次47.5 mg,每日1次,早上服用,疗程为90 d。疗程结束后,对比分析两组的临床治疗效果。结果治疗后,联合治疗组的总有效率为90.91%(60/66),显著高于美托洛尔单用组的68.18%(45/66),差异有统计学意义(P<0.01)。治疗前后,在糖化血红蛋白(Hb A1c)、空腹血糖(FBG)、舒张压、收缩压方面进行比较,联合用药治疗组[(7.68±1.10)%vs(6.85±1.01)%]、[(8.35±1.33)mmol/L vs(7.06±0.56)mmol/L]、[(98.31±11.40)mm Hg vs(83.68±10.02)mm Hg]、[(144.07±11.94)mm Hg vs(119.68±10.29)mm Hg]和美托洛尔单用组[(7.66±1.07)%vs(7.22±0.99)%]、[(8.33±1.31)mmol/L vs(7.35±0.82)mmol/L]、[(98.36±11.38)mm Hg vs(88.03±10.32)mm Hg]、[(144.23±12.43)mm Hg vs(128.27±10.35)mm Hg](P<0.05),治疗后,联合用药治疗组患者Hb A1c、FBG、收缩压、舒张压均显著低于美托洛尔单用组,差异有统计学意义(P<0.05)。结论厄贝沙坦联合氨氯地平能够明显改善2型糖尿病合并高血压患者的糖代谢状况和血压水平,是一个理想的治疗方案。

Clinical Study on Irbesartan Combined with Amlodipine in the Treatment of Type 2 Diabetes with Hypertension

Objective To observe the therapeutic effect of irbesartan combined with amlodipine in the treatment of type 2 diabetes with hypertension. Methods A total of 132 patients in Xuanwu Hospital of Capital Medical University,from Jan. 2011 to Oct. 2012,who suffered type 2 diabetes with hypertension were divided into two groups according to random-number table method,66 patients in each group. The combined treatment group was given irbesartan（ 50 mg per time,3 times per day） combined with amlodipine（ 2. 5 mg per time,1 time per day） for 90 d as a course,the metoprolol single group was only given metoprolol（ 47. 5mg per time,1 time per day） for 90 d as a course. The treatment effect of the two groups was analyzed and compared at the end of a course of treatment. Results After the treatment,the total effective rate of the combined treatment group was 90. 91%（ 60 /66）,while the control group was 68. 18%（ 45 /66）,the former group was significantly higher than the latter group（ P〈0. 01）. Hb A1 c,FBG,diastolic pressure,systolic pressure of the combined treatment group before and after treatment were [（ 7. 68 ± 1. 10） % vs（ 6. 85 ±1. 01） % ],[（ 8. 35 ± 1. 33） mmol / L vs（ 7. 06 ± 0. 56） mmol / L],[（ 98. 31 ± 11. 40） mm Hg vs（ 83. 68± 10. 02） mm Hg],[（ 144. 07 ± 11. 94） mm Hg vs（ 119. 68 ± 10. 29） mm Hg],of the metoprolol single treatment group were[（ 7. 66 ± 1. 07） % vs（ 7. 22 ± 0. 99） ],[（ 8. 33 ± 1. 31） mmol / L vs（ 7. 35 ± 0. 82）mmol / L],[（ 98. 36 ± 11. 38） mm Hg vs（ 88. 03 ± 10. 32） mm Hg ],[（ 144. 23 ± 12. 43） mm Hg vs（ 128. 27 ± 10. 35） mm Hg],（ P〈0. 05）,and the former groupwas improved more remarkably,with lower levels（ P〈0. 05）. Conclusion Irbesartan combined with amlodipine could ameliorate glucose metabolism and blood pressure of patients who have type 2 diabetes with hypertension,thus is an ideal therapeutic regimen.